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KEY POINTS: 
• Ruxolitinib caused DNA repair defects and sensitized MPN stem and progenitor cells to 
PARP inhibitors. 
• Quiescent and proliferating MPN cells were eliminated by ruxolitinib and olaparib +/- 
hydroxyurea. 
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Abstract 
Myeloproliferative neoplasms (MPNs) often carry JAK2(V617F), MPL(W515L), or CALR(del52) 
mutations. Current treatment options for MPNs include cytoreduction by hydroxyurea and 
JAK1/2 inhibition by ruxolitinib, both of which are not curative. We show here that cell lines 
expressing JAK2(V617F), MPL(W515L) or CALR(del52) accumulated reactive oxygen species-
induced DNA double-strand breaks (DSBs) and were modestly sensitive to poly-ADP-ribose 
polymerase (PARP) inhibitors olaparib and BMN673. At the same time primary MPN cell 
samples from individual patients displayed a high degree of variability in the sensitivity to these 
drugs. Ruxolitinib inhibited two major DSB repair mechanisms, BRCA-mediated homologous 
recombination and DNA-PK –mediated non-homologous end-joining and, when combined with 
olaparib, caused abundant accumulation of toxic DSBs resulting in enhanced elimination of 
MPN primary cells, including the disease-initiating cells from the majority of patients. Moreover, 
the combination of BMN673, ruxolitinib and hydroxyurea was highly effective in vivo against 
JAK2(V617F)-positive murine MPN-like disease and also against JAK2(V617F), CALR(del52), 
and MPL(W515L)-positive primary MPN xenografts. In conclusion, we postulate that ruxolitinib-
induced deficiencies in DSB repair pathways sensitized MPN cells to synthetic lethality triggered 
by PARP inhibitors. 
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Introduction 
Philadelphia chromosome-negative (Ph-) myeloproliferative neoplasms (MPNs) include 
polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), 
which are associated with mutations in JAK2, CALR and MPL genes 1,2. Current treatment 
options for Ph- MPNs include cytoreductive therapy with hydroxyurea, and the JAK1/2 inhibitor 
(JAK1/2i) ruxolitinib, which produce durable reductions in splenomegaly and improvement of 
symptoms and probably of survival, but do not eliminate the disease-initiating cell population 3,4. 
MPNs usually present in chronic phase, but they may eventually accelerate and transform into 
secondary acute myeloid leukemia which carries a dismal prognosis and is always fatal 5. 
Therefore, it is imperative to generate new therapies, which alone or in combination with 
conventional treatments induce long-term remission, even in patients who have progressed to 
the acute leukemia stage. The combination of agents which target different mechanisms 
promises to provide a successful rational future strategy 6. 
MPN cells contain elevated levels of reactive oxygen species (ROS) and stalled replication 
forks, resulting in accumulation of high numbers of toxic DNA double-strand breaks (DSBs) 7-12. 
Therefore, we reasoned that MPN cell survival may depend on DSB repair mechanisms 13-21. 
DSBs are repaired by two major mechanisms, BRCA1/2-mediated homologous recombination 
repair (HRR) and DNA-PKcs-mediated non-homologous end-joining (D-NHEJ) 22. In addition, 
poly-ADP-ribose polymerase 1 (PARP1) plays a central role in preventing/repairing lethal DSBs 
by activation of base excision repair/single-stranded DNA break repair, by stimulation of fork 
repair/restart, and by mediating the back-up NHEJ (B-NHEJ) repair 23-26. 
Accumulation of potentially lethal DSBs in MPN cells could create an opportunity to 
eliminate these cells by targeting DNA repair mechanisms. Here, we tested the hypothesis that 
combination of ruxolitinib-mediated inhibition of DSB repair with a PARP inhibitor (PARPi) 
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and/or hydroxyurea causes accumulation of lethal DSBs beyond reparable thresholds resulting 
in enhanced elimination of MPN cells. 
Materials and Methods 
Primary cells 
Peripheral blood and bone marrow samples from patients with newly diagnosed MPNs 
(Supplementary Table 1) were obtained from: (1) Department of Biomedicine, Basel University, 
Switzerland, (2) Department of Internal Medicine, Hematology and Oncology, Medical 
University, Aachen, Germany, (3) Department of Hematology, University of Cambridge, UK, and 
(4) Myeloproliferative Disorders Clinic, Huntsman Cancer Hospital, Salt Lake City, UT, USA. 
Samples of normal hematopoietic cells were purchased from Cambrex Bio Science 
(Walkersville, MD, USA). Lin-CD34+ cells were obtained from mononuclear fractions by 
magnetic sorting using the EasySep negative selection human progenitor cell enrichment 
cocktail followed by human CD34 positive selection cocktail (StemCell Technologies) as 
described before 27. 
Cell lines 
BaF3-JAK2(V617F)+EpoR, 32Dcl3-MPL(W515L), 32Dcl3-CALR(del52)+MPL(wt) cell lines, and 
their BaF3-EpoR and 32Dcl3-MPL(wt) parental counterparts were described before 28-30. BaF3-
HR2 and Jak2(V617F)-positive BaF3-HR2 cells carrying genome-integrated HR-EGFP cassette 
were generously provided by Dr W. Vainchenker 31. They were cultivated in IMDM 
supplemented with 10% FBS, IL-3+Epo, and antibiotic cocktail. 
Inhibitors/drugs 
The following compounds were used: JAK1/2 inhibitor ruxolitinib (Selleckchem), PARP inhibitors 
BMN673 and olaparib (Selleckchem), mutT homologue 1 (MTH1) Inhibitor SCH51344 (Tocris), 
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ROS scavenger vitamin E (Sigma), and ribonucleoside diphosphate reductase inhibitor 
hydroxyurea (Selleckchem). 
Western analyses 
Nuclear cell lysates and total cell lysates were obtained and resolved by SDS-PAGE 
electrophoresis as previously described 27. Protein expressions were analyzed using primary 
antibodies detecting: BRCA1 (#MAB22101, R&D Systems), BRCA2 (#MAB2476, R&D 
Systems), RAD51 (#sc6862, Santa Cruz Biotech.), DNA-PKcs (#A300-518A, Bethyl Lab.), Ku70 
(#A302-623A, Bethyl Lab.), Ku80 (#MA5-15873, ThermoFisher Scientific), PARP1 (#sc7150, 
Santa Cruz Biotech), PALB2 (#A302-627A, Bethyl Lab.), Lig3 (#GTX70147, GeneTex), Lig4 
(#ab26039, Abcam), STAT5 (#SC-28685, Santa Cruz), phospho-STAT5A (Ser780) (#sc-
101805, Santa Cruz), cleaved caspase-3 (#9661, Cell Signaling), lamin B (#sc-6216, Santa 
Cruz), and beta-actin (#A5316, Sigma). 
Examination of DSB repairs 
Cells were cultured in IMDM supplemented with 10% FBS, IL-3 and Epo in the presence or 
absence of 0.15 µM roxulitinib. HRR events were measured as described before with 
modification 32. Five million JAK2(V617F)-positive Ba/F3-HR2 cells carrying  HR-EGFP cassette 
were nucleofected with 5 µg of pCBASCE1 and 2.5 µg of pDsRED-Mito plasmids using 
Nucleofector (Lonza; program U-008, Human CD34 Cell Nucleofector® Kit). Expression of I-
SceI causes a DSB in the specific restriction site included in the HR-EGFP cassette, and 
pDsRed1-Mito encodes red fluorescent protein with a mitochondrial localization signal to control 
the efficiency of transfection. HRR event restores functional EGFP expression, which is readily 
detected by fluorescent microscope 48h after transfection with I-SceI. After 72 hours, cells were 
analyzed by flow cytometry for the percentage of GFP+ cells to assess HRR activity. D-NHEJ 
was measured in cell-free extracts as described before with modification 32. Briefly, 200ng of the 
substrate plasmid (pBluescript KS+ linear plasmids digested XhoI+XbaI to generate non-
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compatible 5’ overhangs) was added to the reaction mix containing 10 μg nuclear lysate and 
incubated for 1h at 37°C. Products of D-NHEJ reaction were resolved in 0.5% agarose gel 
containing 0.5μg/ml of ethidium bromide, scanned with Adobe Photoshop and analyzed by 
ImageQuant TL (Amersham Bioscience, Piscataway, NJ, USA). 
In vitro treatment 
Cells were cultivated in IMDM supplemented with 10% FBS and growth factors [100 ng/ml SCF; 
10 ng/ml Flt3 ligand; 20 ng/ml IL-3, IL-6, G-CSF and GM-CSF; 12 units/ml EPO; 2.5 ng/ml 
TPO]. Ruxolitinib, hydroxyurea, vitamin E, SCH51344, olaparib and/or BMN673 were added for 
3-5 days followed by trypan blue exclusion counting and/or plating in methylcellulose in the 
presence of growth factors. Colonies were counted after 7-10 days. For quiescent/proliferating 
cells, Lin- cells were stained with cell trace violet (CTV) (eBioscience) and incubated for 5 days 
in StemSpan®SFEM medium (Stem Cell Technologies, Vancouver, Canada) supplemented 
with the cocktail of growth factors (see above) and inhibitors when indicated. Quiescent 
(CTVmax) and proliferating (CTVlow) leukemia cells were detected by flow cytometry using 
fluorochrome-conjugated anti-Lin (#340546), anti-CD34 (#347203) and anti-CD38 (#555460) 
antibodies (all from BD Biosciences) as described before 33. 
GFP+JAK2(V671F) murine MPN-like disease 
C57BL/6 recipient mice (The Jackson Laboratories) were subjected to 900 Gy total body 
irradiation followed by i.v. injection of 1:1 mixture of 106 GFP+JAK2(V671F) and 106 wild-type 
bone marrow cells as described before 3. Five weeks later mice were treated with vehicle, 
hydroxyurea (30 mg/kg BID i.p.), ruxolitinib (30 mg/kg BID by oral gavage), BMN673 (0.33 
mg/kg i.v.), and combinations of these drugs for 3 weeks. GFP+JAK2(V617F) cells were 
examined among total bone marrow cells, splenocytes and peripheral blood leukocytes at the 
end of treatment; in addition a fraction of GFP+JAK2(V617F) Lin-Sca1+c-Kit+ cells was assessed 
in the bone marrow population. 
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Primary MPN xenografts 
NOD.Rag1-/-;γcnull mice expressing human IL-3, GM-CSF and SCF (NRGS mice 34, The Jackson 
Laboratories) were sub-lethally irradiated (600 Gy) and injected with 1 x 106 Lin-CD34+ primary 
MPN cells expressing JAK2(V617F), CALR(del52) or MPL(W515L). Three weeks later mice 
were treated as described above with vehicle, hydroxyurea + ruxolitinib, BMN673, and 
hydroxyurea + ruxolitinib + BMN673 for 3 weeks. Human CD45+ (hCD45+) cells, hCD45+Lin-
CD34+ MPN progenitors and stem cell-enriched hCD45+Lin-CD34+CD38- MPN cells were 
detected in bone marrow cells, splenocytes and/or peripheral blood leukocytes at the end of 
treatment as described before 33. 
Statistical analyses 
Data are presented as mean ± standard deviation (SD) from three independent experiments 
and were compared using the unpaired two-tailed Student t test; p values less than 0.05 were 
considered significant. The response additivity approach was used to study the synergistic 
effects 35. This approach shows a positive drug combination effect when the observed 
combination effect is greater than the expected additive effect by the sum of the individual 
effects. The p-value for the possible synergistic effect is given by the significance of the 
interaction effect in a factorial analysis of variance of the individual and combination effects. 
Study Approval 
Studies involving human samples were approved by the Temple University Institutional Review 
Board and met all requirements of the Declaration of Helsinki. Animal studies were approved by 
the Temple University Institutional Animal Care and Use Committee. 
 
Results 
Wide-range sensitivity of MPN cells to PARP inhibitors 
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Murine cell lines expressing JAK2(V617F)+EpoR, MPL(W515L), and CALR(del52)+MPL(wt) 
displayed modestly increased (by 20-40%), but statistically significant (p≤0.002) sensitivity to 
PARP inhibitors olaparib and BMN673 when compared to non-transformed counterparts (Figure 
1A). ROS scavenger vitamin E diminished, whereas MTH1 inhibitor SCH51344 (MTH1 sanitizes 
oxidized dNTP pools to prevent incorporation of damaged bases during DNA replication 36) 
enhanced the toxic effect of olaparib in JAK2(V617F)+EpoR, MPL(W515L) and 
CALR(del52)+MPL(wt) cells. 
Most of key proteins regulating major DSB repair pathways, HR, D-NHEJ and B-NHEJ were 
either not affected or upregulated in the presence of JAK2(V617F), MPL(W515L) and 
CALR(del52) (Figure 1B). However, it appears that expression of MPL(W515L) caused 
approximately 2-fold reduction of the expression of BRCA1 and BRCA2 proteins. Since 
activation of MPL is associated with upregulation of D-NHEJ 37, it is plausible that BRCA1/2-
mediated HR plays a secondary role in DSB repair in MPL(W515L)-positive cells as reflected by 
downregulated BRCA proteins. 
Next, the sensitivity to PARP inhibitors of primary Lin-CD34+ cells from healthy donors and 
MPN patients expressing JAK2(V617F), MPL(W515L), and CALR(del52) were tested in a 
clonogenic assay (Figure 2). Lin-CD34+ cells isolated from healthy donors were only partially 
sensitive to olaparib and BMN673 (Figure 2A). Eight JAK2(V617F) samples (6109-K, 013-S, 
034-S, 8729-K, 338-S, 742-K, 4082-K, 1-P) were sensitive, whereas 3 samples (288-S, 4552-K, 
10141-K) were only partially sensitive to olaparib and BMN673 (Figure 2B). On the other hand, 
CALR(del52) samples displayed highest variability in sensitivity to PARP inhibitors, from 
sensitive (168-S and CV096-G), partially sensitive (055-S, 073-S, 215-S), to resistant (109-S) 
(Figure 2C). MPL(ex10mut) samples behaved similar to JAK2(V617F) samples by being 
sensitive (PF4594-G, BT74-G, MB76-G, BA7621-G) or partially sensitive (RB3382-G)  to PARP 
inhibitors (Figure 2D).  
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Ruxolitinib inhibited DSB repair and enhanced the sensitivity of MPN cells to PARP 
inhibitors 
BaF3-JAK2(V617F)+EpoR, 32Dcl3-MPL(W515L), and 32Dcl3-CALR(del52)+MPL(wt) cells 
treated with olaparib and/or ruxolitinib accumulated elevated numbers of DSBs, especially in 
cells treated with ruxolitinib and olaparib (Figure 3A, upper panel). In addition, enhanced 
accumulation of DSBs in ruxolitinib + olaparib –treated JAK2(V617F)+EpoR, MPL(W515L) and 
CALR(del52)+MPL(wt) –positive cells was associated with synergistic increase of cell death 
(Figure 3A, lower panel). 
To determine if ruxolitinib-mediated accumulation of olaparib-induced DSBs is associated 
with inhibition of DSB repair activity we performed a Western blot array to assess expression of 
key proteins in DSB repair pathways. JAK2(V617F)+EpoR, MPL(W515L), and 
CALR(del52)+MPL(wt) –positive cells and their parental counterparts were treated with 
ruxolitinib for 24 hrs in the presence of IL3 + Epo to inhibit JAK2 kinases as documented by 
downregulated phospho-STAT5A(Ser780) (Figure 3B). At the same time, ruxolitinib-treated cells 
were viable as assessed by Trypan blue exclusion, minimal caspase-3 activation, and 
uncleaved PARP1. Key proteins in HRR (BRCA1 and RAD51) and D-NHEJ (Lig4), but not B-
NHEJ were downregulated in ruxolitinib-treated JAK2(V617F)+EpoR, MPL(W515L), and 
CALR(del52)+MPL(wt) –positive cells (Figure 3B). 
Next, we examined if ruxolitinib-induced downregulation of RAD51 and LIG4 proteins 
(Figure 3C, upper panel) caused reduction of HRR and D-NHEJ activities. D-NHEJ activity 
measured in vitro by nuclear cell lysate –mediated plasmid end-joining was inhibited by 
approximately 3-fold in ruxolitinib-treated JAK2(V617F)-positive cells (Figure 3C, middle panel). 
To measure HRR activity an I-SceI endonuclease-mediated DSB was induced in Jak2(V617F)-
positive Ba/F3-HR2 cells carrying HR-EGFP recombination reporter cassette integrated in their 
genome. HRR restores the expression of GFP detected by flow cytometry. Ruxolitinib-treated 
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Ba/F3-HR2 cells displayed approximately 2-fold reduction in HRR activity (Figure 3C, lower 
panel). 
We have previously reported that D-NHEJ-deficient quiescent and HRR/D-NHEJ-
deficient proliferating tumor cells were sensitive to dual cellular synthetic lethality exerted by 
PARPi 33. Therefore, we tested if ruxolitinib-induced downregulation of D-NHEJ and HRR 
sensitize JAK2(V617F)-positive quiescent and proliferating cells, respectively, to PARPi-
mediated synthetic lethality. Intriguingly, ruxolitinib enhanced the sensitivity of LSCs-enriched 
Lin-CD34+CD38-CTVlow proliferating patient cells to olaparib (Figure 3D,E). Moreover, even if 
individual drugs did not affect LSCs-enriched Lin-CD34+CD38-CTVmax quiescent cells, the 
combination exerted synergistic inhibitory effect (Figure 3D,E). 
Ruxolitinib enhanced the effect of PARP inhibitors and/or hydroxyurea in vitro in pre-
selected MNP samples 
Clonogenic assay revealed that Lin-CD34+ primary MPN cells from a cohort of MPNs expressing 
JAK2(V617F), MPL(ex10mut), and CALR(del52), which were sensitive to PARPi (Figure 2B-D, 
optimal response), responded favorably to the combination of ruxolitinib + olaparib and 
ruxolitinib + hydroxyurea + olaparib (034-S, 338-S, 742-K, 013-S, 4082-K, 6109-K, 8729-K, 168-
S, CV096-K, PF4594-G, BT74-G, MB76-G, BA7621-G in Figure 4A-C, D-left panel). On the 
other hand, cells from samples displaying partial sensitivity or resistance to PARPi (suboptimal 
response) could be sub-divided in to two cohorts: these which responded favorably (055-S, 215-
S in Figure 4A-C, D-middle left panel) or unfavorably (10141-K, 5442-K, 288-S, 073-S, 109-S, 
RB3382-G in Figure 4A-C, D- middle right panel) to ruxolitinib + olaparib and/or ruxolitinib + 
hydroxyurea + olaparib. Lin-CD34+ cells from 3 healthy donors displayed homogenous response 
pattern to the drugs (Figure 4D- right panel), similar to that of unfavorable MPN cohort (Figure 
4D- middle right panel). 
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Ruxolitinib enhanced the effect of PARP inhibitors and/or hydroxyurea in a retroviral 
murine model of JAK2(V617F)-positive MPN 
To test if ruxolitinib enhances the effect of PARPi +/- standard cytotoxic drug hydroxyurea, we 
applied a murine model of GFP+JAK2(V617F)-positive PV (Figure 5A) 3. BMN673 was used 
here because it displays better pharmacokinetic parameters in mice than olaparib 38. As 
expected, ruxolitinib and hydroxyurea when used individually did not reduce the percentage of 
GFP+JAK2(V617F)-positive cells in peripheral blood, spleen and bone marrow, and BMN673 
exerted only a very moderate inhibitory effect (Figure 5B-D). However, ruxolitinib significantly 
enhanced the therapeutic effect of BMN673 and of BMN673 plus hydroxyurea. In addition, the 
population of stem cell-enriched GFP+Lin-Sca-1+c-Kit+ JAK2(V617F) cells was significantly 
reduced in mice treated with ruxolitinib combined with BMN673 or BMN673 + hydroxyurea when 
compared to BMN673 +/- hydroxyurea (Figure 5E). 
Major organs such as heart, lungs, liver, kidneys, bone marrow and spleen in mice 
treated with combination of ruxolitinib, hydroxyurea and BMN67 showed normal morphologic 
features with no evidence of ischemia or drug toxicity (Supplementary Figure S1). More detailed 
analysis of hematopoietic system revealed only transient moderate toxicity in peripheral blood 
and bone marrow (Supplementary Table 2). 
In vivo PARP inhibitor treatment enhanced the effect of ruxolitinib + hydroxyurea against 
pre-selected primary MPN xenografts in immunodeficient mice 
Primary MPN samples [JAK2(V617F) –positive 6109-K, MPL(ex10mut)-positive PF4594-G, and 
CALR(del52)-positive 168-S] were pre-selected based on their favorable response to PARPi +/- 
ruxolitinib and hydroxyurea (Figure 2B-D and 4A-C). Primary Lin-CD34+ MPN cells from these 
patients also engrafted in NRGS mice (>5% hCD45+ cells in peripheral blood and splenomegaly 
after 3 weeks). NRSG mice bearing these MPN xenografts were treated with vehicle (Control), 
hydroxyurea + ruxolitinib (HR), BMN673, or HR + BMN673 (Figure 6A). The therapeutic effect 
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was measured by detection of hCD45+ cells in peripheral blood, spleen and bone marrow, and 
of hCD45+Lin-CD34+ and hCD45+Lin-CD34+CD38- cells in bone marrow. 
Ruxolitinib + hydroxyurea did not consistently reduce the percentage and number of 
MPN xenograft cells (Figure 6B). On the other hand BMN673 reduced the percentage of 
hCD45+ cells in peripheral blood, spleen and bone marrow, and the number of hCD45+Lin-
CD34+ and hCD45+Lin-CD34+CD38- cells in bone marrow of mice bearing JAK2(V617F), 
MPL(ex10mut), and CALR(del52)-positive MPN xenografts. Importantly, the combination of 
BMN673 + ruxolitinib + hydroxyurea exerted the strongest anti-MPN effect when compared to 
BMN673 and ruxolitinib + hydroxyurea. 
Discussion 
Our data and other reports indicated that MPN cells contain elevated levels of ROS and stalled 
replication forks, resulting in accumulation of potentially lethal DSBs 8,12. However, MPN cells 
are able to repair numerous DSBs because two major DSB repair pathways, HRR and D-NHEJ, 
are activated 31,37. PARPi and/or hydroxyurea generate additional DSBs which may overwhelm 
DSB repair activity in some MPN cells to cause cell death 39,40, but numerous cells can survive 
the treatment. 
We have shown here that JAK1/2 kinase inhibitor ruxolitinib caused downregulation of 
key members of HRR (BRCA1, RAD51) and D-NHEJ (LIG4) in JAK2(V617F), MPL(ex10mut), 
and CALR(del52)-positive cell lines resulting in reduced HRR and D-NHEJ activities. This effect 
was associated with PARPi-induced accumulation of DSBs and enhanced elimination of MPN 
cells from numerous patient samples. Since defects in DNA repair sensitized tumor cells to 
PARPi, we postulate that ruxolitinib-induced HRR and D-NHEJ -deficiencies triggered PARPi-
mediated synthetic lethality 41. 
All three “driver” mutations, [JAK2(V617F), CALR(del52), and MPL(W515L)] have been 
detected not only in mature MPN cells, but also in MPN stem cells, and therefore these cells 
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must be eliminated to eradicate the disease 42-45. Since JAK1/2i did not eliminate the disease-
initiating population novel therapeutic approaches were needed 4.  
Ruxolitinib treatment inhibits proliferation of JAK2(V617), CALR(del52) and 
MPL(W515L)-positive cells, but induce minimal degrees of apoptosis (46 and Supplementary 
Figure S2), and growth-arrested cells usually show poor sensitivity to cytotoxic drugs. We 
observed that ruxolitinib reduced the activity of DSB repair pathways playing a key role in 
proliferating (HRR/D-NHEJ) and quiescent (D-NHEJ) cells. We postulate that ruxolitinib-
mediated inhibition of HR and D-NHEJ creates a unique opportunity to trigger PARPi-mediated 
dual synthetic lethality in HRR and D-NHEJ –deficient proliferating cells and in D-NHEJ –
deficient G1/G0 cells expressing the “driver” mutations. 
This statement is supported by 5 observations: (1) quiescent and proliferating Lin-
CD34+CD38- human MPN-initiating cells 42 were eliminated in vitro by ruxolitinib + olaparib, (2) 
Lin-Sca-1+c-Kit+ murine MPN initiating cells 4,43 were eliminated by ruxolitinib + BMN673 +/- 
hydroxyurea in syngeneic mice bearing JAK2(V617F)-positive MPN-like disease, (3) Lin-
CD34+CD38- human MPN-initiating cells were eliminated by ruxolitinib + BMN673 +/- 
hydroxyurea in NRGS mice bearing primary MPN xenografts, (4) disease-initiating cells capable 
to engraft secondary recipient mice were eliminated by ruxolitinib + BM3673 + hydroxyurea in 
NRGS mice bearing primary MPN xenograft (Supplementary Figure S3), and (5) we reported 
that PARPi eliminated HRR/D-NHEJ deficient proliferating and D-NHEJ deficient quiescent 
acute and chronic leukemia cells 33. It has been reported that interferon alpha, which to date 
shows the highest degree of molecular remissions among the conventional drugs used to treat 
MPN patients, induced proliferation of JAK2(V617F) disease-initiating cells and promoted a 
predetermined erythroid differentiation 47. Our approach directly eliminates both proliferating and 
quiescent MPN-initiating cells, thus significantly expanding the MPN cells that can be targeted 
to the most primitive cell population. 
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Individual MPN samples displayed high level of variability in responding to PARPi. 
Another report supported this observation and suggested that sensitivity to PARPi was 
associated with impaired HRR 48. Ruxolitinib induced HRR and D-NHEJ deficiency and 
enhanced sensitivity to PARPi in numerous patient samples which displayed optimal and sub-
optimal response to PARPi used alone. However, a cohort of MPN samples with sub-optimal 
response to PARPi remained partially resistant to the inhibitor even when combined with 
ruxolitinib. There are several possible explanations for the heterogeneous response of individual 
MPNs to PARPi or ruxolitinib + PARPi. 
First, additional genetic/epigenetic factors inherently characteristic for individual MPNs 
[e.g., mutations in TET2, ASXL1, DNMT3A, EZH2, IDH1 2] may regulate sensitivity to PARPi +/- 
ruxolitinib. This is supported by the data suggesting that TET2 affects the response of 
JAK2(V617F)-positive murine bone marrow cells to olaparib +/- ruxolitinib (Supplementary 
Figure S4), that mutations in DNMT3a and IDH1 altered DNA repair activity and sensitivity to 
PARPi and anthracycyline 49-51, and that EZH2 downregulates the expression of BRCA1 and 
RAD51 52-55. In addition, deletion of Asxl1 and/or Tet2 deregulated expression of DNA repair 
genes including Rad51 in Lin-Sca-1+c-Kit+ murine bone marrow cells 56. The hypothesis that 
accompanying mutations may modulate sensitivity of MPN cells to PARPi +/- JAK1/2i is further 
supported by our data from primary cells indicating that TET2mut, EZH2mut and ASXL1mut 
may enhance while DNMT3Amut alone and RUNX1mut may diminish sensitivity to PARPi used 
as single agents and also combined with ruxolitinib +/- hydroxyurea (Supplementary Figure S5). 
In addition, mutations in the BRCA1-BRCA2-containing complex 3 (BRCC3) gene implicated in 
DNA repair are frequently concomitant with JAK2 and MPL mutations and may modulate the 
sensitivity to PARPi 57. 
Although heterozygosity/homozygosity of the mutated “driver” allele does not appear to 
regulate sensitivity to olaparib (Supplementary Figure S6A), it may affect the response to the 
combination of ruxolitinib + hydroxyurea + olaparib (Supplementary Figure S6B). The mutant 
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allele burden did not appear to influence PARPi efficacy (Supplementary Figure S7, Figure 2 
and Supplementary Table 1). 
In conclusion, we demonstrated that JAK1/2i-induced DNA repair deficiencies may be 
clinically explored in pre-selected MPN patients treated with a combination of ruxolitinib and, as 
innovative therapeutic approach, PARPi +/- hydroxyurea to enhance elimination of MPN-
initiating and progenitor cell populations. All of these drugs have been approved as therapeutic 
agents in oncology thus facilitating such a clinical trial. Moreover, similar therapeutic approach 
could be undertaken also in other hematological malignancies displaying constitutive activation 
of JAK kinases either by direct mutation [e.g., JAK2(R683S) in pediatric acute lymphoblastic 
leukemia 58 and JAK3(A572V) in acute megakaryocytic leukemia 59] or by activating mutation 
upstream of JAK kinases [e.g., CSF3R(T618I) in chronic neutrophilic leukemia 60], because cells 
lines transformed with these mutants were sensitive to the combination of ruxolitinib and 
olaparib (Supplementary Figure S8). 
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Figure legends: 
Figure 1. Sensitivity of JAK2(V617F), CALR(del52), and MPL(ex10mut) -positive cells to 
PARP inhibitors. (A) Cell lines expressing JAK2(V617F)+EpoR, CALR(del52) + MPL(wt), or 
MPL(W515L) were incubated with olaparib alone (1.25, 2.5, 5.0 μM) (squares) or BMN673 
alone (12.5, 25.0, 50.0 nM) (squares), olaparib + 200 μM vitamin E (circles), or olaparib + 2.5 
μM SCH51344 (triangles) for 96 hrs in the presence of IL-3 + Epo. Parental cells (diamonds) 
were incubated with olaparib or BMN673 only. Living cells were counted in Trypan blue. Results 
represent mean ± SD percent of living cells in comparison to untreated control from 3 
independent experiments. (B) Western analysis of the indicated proteins in parental cells (P) 
and in isogenic cells expressing JAK2(V617F)+EpoR, CALR(del52)+MPL(wt) and MPL(W515L). 
 
Figure 2. Sensitivity of individual MPN samples expressing JAK2(V617F), CALR(del52), 
and MPL(ex10mut) to PARP inhibitors. Lin-CD34+ primary cells from (A) healthy donors (n=3) 
and from (B) JAK2(V617F), (C) CALR(del52), (D) MPL(ex10mut) –positive MPN patients were 
incubated with olaparib (1.25, 2.5, 5.0 μM) or BMN673 (12.5, 25.0, 50.0 nM) for 96 hrs in the 
presence of growth factors [100 ng/ml SCF; 10 ng/ml Flt3 ligand; 20 ng/ml IL-3, IL-6, G-CSF 
and GM-CSF; 12 units/ml EPO; 2.5 ng/ml TPO] followed by plating in methylcellulose. Colonies 
were counted after 7-10 days. Results represent % of colonies in comparison to untreated 
control. 
 
 
Figure 3. JAK2 kinase inhibitor ruxolitinib reduced HRR and D-NHEJ activity and 
enhanced the anti-MPN effect of PARP inhibitor olaparib. (A) Parental cell lines and these 
expressing JAK2(V617F)+EpoR, CALR(del52) + MPL(wt), or MPL(W515L) were untreated (C) 
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or treated with 5μM olaparib (O) or 400 nM ruxolitinib (R) or ruxolitinib + olaparib  (R+O) in the 
presence of IL-3 + Epo for 24 hrs (γ-H2AX) and 96 hrs (cell survival). DSBs were detected by γ-
H2AX immunofluorescence overlapping with DAPI (upper panel), and living cells were counted 
in Trypan blue (lower panel; percent of living cells in comparison to untreated control). Results 
represent means ± SD from 3 independent experiments. *p<0.05 in comparison to C using 
Student t test; **p≤0.001 in comparison to R and O groups using the response additivity 
approach. (B) Western analysis of the indicated proteins in cells expressing 
JAK2(V617F)+EpoR, CALR(del52)+MPL and MPL(W515L), and in BaF3-EpoR cells (Parental) 
after 24 hrs incubation with 400 nM ruxolitinib in the presence of IL-3 + Epo. Proteins 
downregulated by ruxolitinib are in red boxes. (C) HRR and D-NHEJ activities in JAK2(V617F)-
positive cells untreated (-) or treated for 24 hrs with 400 nM ruxolitinib (+). Upper panel: Western 
blots, Middle panel: D-NHEJ activity, S – linearized plasmid substrate, P – ligated plasmid 
products, results show % of P; Lower panel: HRR activity measured by restoration of EGFP 
expression, results show % of GFP+ cells; *p≤0.01. (D) Number of proliferating Lin-CD34+CD38-
CTVlow and quiescent Lin-CD34+CD38-CTVmax cells from individual JAK2(V617F)-positive MPN 
samples left untreated (C) or treated with ruxolitinib (R, 25 nM), olaparib (O, 1.25 μM) and 
ruxolitinib + olaparib (R+O). (E) Cumulative percentages from samples examined in panel D; 
*p<0.001 in comparison to R or O groups using Student t test; **p<0.01 in comparison to R and 
O groups using the response additivity approach. 
 
Figure 4. The effect of ruxolitinib on the sensitivity of JAK2(V617F), CALR(del52), and 
MPL(ex10mut) MPN cells to PARP inhibitors. Lin-CD34+ cells from PV, ET and MF patients 
carrying (A) JAK2(V617F), (B) CALR(del52), and (C) MPL(ex10mut) were incubated with 
olaparib (O, 1.25 μM), hydroxyurea (H, 10 μM) and/or ruxolitinib (R, 25 nM) for 72 hrs in the 
presence of growth factors (see Figure 2) and plated in methylcellulose. Colonies were counted 
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after 7-10 days. Results represent mean number of colonies ± SD from triplicates. (D) 
Ruxolitinib (R)-treated Lin-CD34+ cells from cohorts of MPN samples (black bars) and healthy 
donors (grey bars) displayed heterogenic sensitivity to PARP inhibitor; *p<0.05 in comparison to 
O and **p<0.05 in comparison to HO using Student t test. 
 
Figure 5. BMN673 exerted anti-MPN effect in vivo. (A) Experimental model. Lethally 
irradiated C57BL/6 recipient mice were injected with 1:1 mixture of 106 GFP+JAK2(V671F) and 
106 wild-type bone marrow cells. Five weeks later mice were treated with vehicle (C), 
hydroxyurea (H; 30 mg/kg BID i.p.), ruxolitinib (R; 30 mg/kg BID oral gavage), BMN673 (B; 0.33 
mg/kg i.v.), H+R, H+B, R+B, and H+R+B for 3 weeks. Percent of GFP+JAK2(V617F) was 
measured in (B) bone marrow cells, (C) splenocytes, and (D) peripheral blood leukocytes; (E) 
number of GFP+JAK2(V617F) Lin-Sca1+c-Kit+ (LSK) cells per 106 bone marrow cells was 
calculated, too. *, **, and *** - p<0.05 when compared to control, single treatment and double 
treatment, respectively, from 6-7 mice using Student t test. 
 
Figure 6. BMN673 exerted anti-MPN xenograft effect in vivo. (A) Experimental model. Sub-
lethally irradiated NRGS recipient mice were injected with 106 primary Lin- MPN cells from 
individual MPN patients expressing JAK2(V617F), CALR(del52), or MPL(W515L). One week 
later mice were treated with vehicle (C), hydroxyurea (H; 30 mg/kg BID i.p.) + ruxolitinib (R; 30 
mg/kg BID oral gavage) (HR), BMN673 (B; 0.33 mg/kg i.v.) and HR+B (HRB) for 3 weeks (3-5 
mice/group). Indicated cells were detected by immunofluorescence. (B) Percent of hCD45+ 
cells was measured in peripheral blood leukocytes (PBLs), splenocytes (SPLs) and bone 
marrow cells (BMCs). Number of hCD45+ BMCs expressing Lin-CD34+ and Lin-CD34+CD38- per 
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106 cells were determined. * and ** - p<0.05 in comparison to C and all other groups, 
respectively, using Student t test. 
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